Morgan Stanley Raises its Price Target on Alnylam (ALNY)

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is one of the 10 Best Growth Stocks With Highest Upside Potential.

On July 10, 2026, Morgan Stanley raised the firm’s price target on Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) to $400 from $370 and kept an Equal Weight rating on the shares.

On July 9, Raymond James raised the firm’s price target on Alnylam to $468 from $420 and kept an Outperform rating on the shares. Raymond James said Ionis’ (IONS) failed Phase 3 ATTR-CM trial strengthens Alnylam’s competitive position by reducing a key rival to its TTR silencer franchise and improving the outlook for pricing. The firm also noted that the results may raise some risk for Alnylam’s next-generation nucresiran trial in patients receiving background tafamidis.

Morgan Stanley Raises its Price Target on Alnylam (ALNY)

On June 29, H.C. Wainwright lowered the firm’s price target on Alnylam to $470 from $510 and kept a Buy rating on the shares. H.C. Wainwright reduced near-term estimates for Amvuttra but continued to estimate Alnylam’s TTR franchise growing to over $20B in annual revenues by 2040.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally.

While we acknowledge the risk and potential of ALNY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ALNY and that has 10,000% upside potential, check out our report about the cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1